Forte Biosciences, Inc.
FBRX
$18.31
-$0.78-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -51.74M | -42.45M | -43.71M | -35.48M | -34.20M |
| Total Depreciation and Amortization | 55.00K | 48.00K | 43.00K | 39.00K | 35.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.89M | 4.22M | 3.52M | 2.94M | 3.18M |
| Change in Net Operating Assets | 2.37M | -370.00K | 5.72M | 1.76M | 1.27M |
| Cash from Operations | -44.43M | -38.56M | -34.43M | -30.75M | -29.71M |
| Capital Expenditure | -147.00K | -92.00K | -92.00K | -37.00K | -23.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 394.00K | 394.00K | 394.00K | -35.96M | 1.00K |
| Cash from Investing | 247.00K | 302.00K | 302.00K | -35.99M | -22.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 129.82M | 128.02M | 53.02M | 53.01M | 223.00K |
| Repurchase of Common Stock | -25.00K | -27.00K | -34.00K | -35.00K | -45.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8.56M | -8.09M | -3.44M | -1.12M | -273.00K |
| Cash from Financing | 121.23M | 119.90M | 49.54M | 51.86M | -95.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 77.05M | 81.65M | 15.41M | -14.88M | -29.82M |